Clinical trials: Oesophageal Cancer Nos
Esophageal Cancer, Esophagogastric Junction Cancer
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
- Trial name
- CRATER (NCT05245760)
- Testing
- Intravenous Tislelizumab, Chemotherapy, Fractionated radiation
- Where
- United States
- Sponsor
- Zhonglin Hao
Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma
The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer
Limited-stage small cell esophageal carcinoma (LS-SCEC) is a rare and highly aggressive malignancy with poor prognosis and no established standard treatment strategy.
- Trial name
- NCT07596654
- Where
- China
- Volunteers
- 4 people
- Sponsor
- yi shen
Hepatocellular Cancer, Cholangiocarcinoma
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
PLATON (Platform for Analyzing Targetable Mutations) is a prospective, multicentre, observational cohort study with biobanking. In a first approach PLATON's pilot-study assesses genomic profiling in gastrointestinal cancer…
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- PLATON (NCT04484636)
- Testing
- FoundationOne®CDx and FoundationOne®Liquid
- Where
- 46 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophageal Cancer
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00072033
- Testing
- Cisplatin and Docetaxel
- Where
- 9 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Swiss Cancer Institute
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Breast Cancer, Lung Cancer
Intra-individual Comparison of Conventional and Digital PET/CT Scanners
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Miscellaneous Neoplasm
- Trial name
- NCT03457506
- Testing
- Digital PET/CT scan
- Where
- Netherlands
- Volunteers
- 225 people
- Sponsor
- Isala
Esophageal Cancer, Gastric Cancer
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Patients can be prescreened for the study at the time of diagnosis of locally advanced or metastatic disease by determining presence of LOH high status and/or deleterious alterations in HR pathway genes in the most recent…
- Conditions
- Esophageal Cancer, Gastric Cancer, Adenocarcinoma
- Trial name
- NCT03840967
- Testing
- Niraparib
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shadia Jalal, MD
Esophageal Cancer
trūFreeze® Palliative Esophageal Cancer
Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent…
- Trial name
- NCT03243734
- Testing
- trūFreeze® System spray cryotherapy
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- US Endoscopy Group Inc.
Esophageal Neoplasms
Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy.
- Trial name
- NCT03254511
- Testing
- Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable, Radiotherapy, Chemotherapeutic Combinations
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Mashhad University of Medical Sciences
Resectable Esophageal Cancer
Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma
The purpose of this study is to determine whether the addition of the combination between cetuximab and radiotherapy to the standard chemotherapy for resectable oesophageal cancer is safe and adds efficacy.
- Trial name
- TRACC (NCT00827671)
- Testing
- cetuximab, radiotherapy to oesophageal tumour
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- P.O. Witteveen
Oesophageal Cancer
Unintentional Weight Loss After Oesophagectomy
The incidence of cancer of the oesophagus is increasing. While surgical removal of the tumour (oesophagectomy) may offer the best chance of cure, such major operations are associated with long-term complications such as poor…
- Trial name
- UWL (NCT05074914)
- Testing
- oesophagectomy
- Where
- Ireland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Lung Cancer, Esophageal Cancer
A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer
This survey study is looking to determine if patient reported outcomes(using the PROMIS survey) will vary according to the presence of recurrent or metastatic lung or esophageal cancer.
- Trial name
- NCT02239328
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- University of Virginia
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07517211
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Esophageal Cancer TNM Staging Primary Tumor (T) T4
Establishing Best Treatment Strategy for T4 Esophageal Cancer
The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy.
- Trial name
- NCT06531434
- Testing
- "Docetaxel", "Cisplatin", "fluorouracil", "Radiation"
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Cheng-Kung University Hospital
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Esophageal Cancer
Evaluation of Polyflex Stenting in Esophageal Cancer Patients
To evaluate the effectiveness of an esophageal stent as a way to maintain nutrition during radiation and/or chemotherapy treatment.
- Trial name
- NCT00727376
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Louisville
Barrett's Esophagus, Gastroesophageal Reflux Disease
Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease
To Compare the overall quality of life of patients with no Barrett's esophagus , non-dysplastic Barrett's Esophagus (NDBE), Barrett's esophagus with low grade dysplasia (LGD), and Barrett's esophagus with high grade dysplasia…
- Trial name
- NCT01572974
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Midwest Biomedical Research
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Solid Organ Cancers
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells.
- Trial name
- NCT02714374
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrew Lowy
Esophageal Cancer
Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer
This multicenter open labeled phase 2 trial examines the efficacy of a combination of Gemcitabine 1000 mg/m2 (30 min), Cisplatin 30 mg/m2 (90 min), Folinic Acid 200 mg/m2 (30 min) and 5-FU 750 mg/m2 (24h CI) all given day 1,8 q…
- Trial name
- CONKO-101 (NCT00759226)
- Testing
- Gemcitabine, Cisplatin, 5-FU
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- CONKO-Studiengruppe
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.